6 news items
Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
BAX
BTAI
EGRX
15 May 24
investigator fabricated email correspondence with a pharmacovigilance safety vendor that was then provided to the FDA; and (v) the above would negatively
BioXcel Therapeutics Reports First Quarter 2024 Financial Results
BTAI
9 May 24
trial: designed to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for agitation associated with Alzheimer's dementia (AAD
BioXcel Therapeutics Announces Late-Breaking Abstract On Preliminary Findings From Phase 2 Investigator-Sponsored Trial Of BXCL701 And KEYTRUDA In Metastatic Pancreatic Ductal Adenocarcinoma Selected For Presentation At 2024 ASCO Annual Meeting
BTAI
24 Apr 24
enrollment in the safety lead-in portion of the trial. Through its OnkosXcel Therapeutics immuno-oncology subsidiary, BioXcel Therapeutics
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
BTAI
24 Apr 24
enrollment in the safety lead-in portion of the trial. Through its OnkosXcel Therapeutics immuno-oncology subsidiary, BioXcel
BioXcel Therapeutics Reveals Plan For Evaluating BXCL501 In The At-Home Setting To Expand Its Market Potential
BTAI
22 Apr 24
Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA
No FDA
yz0un8bf
AMZN
BTAI
CERT
9 Apr 24
Environment
A further noteworthy allocation is the $50 million for establishing an AI safety institute
- Prev
- 1
- Next